New Advances in Follicular Lymphoma: A Focus on the Expanding Role of PI3K Inhibitors

Hear from experts about the emerging clinical trial data on the use of PI3K inhibitors to treat follicular lymphoma in the frontline and relapsed settings and the best practices for selecting candidates for PI3K therapies for selecting appropriate therapies and for managing adverse events. Review their insights in dowloadable slides and an on-demand webcast.

Share

Program Content

No activities added yet

No activities added yet

Provided by

ProCE Banner

Supporters

Supported by educational grants from

Bayer Healthcare Pharma

TG Therapeutics